Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for Cartesian Therapeutics (RNAC) over the last 6 years, with Dec 2024 value amounting to $17.4 million.

  • Cartesian Therapeutics' Shares Outstanding (Diluted Average) rose 21.10% to $26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.0 million, marking a year-over-year increase of 21.10%. This contributed to the annual value of $17.4 million for FY2024, which is 235.72% up from last year.
  • Cartesian Therapeutics' Shares Outstanding (Diluted Average) amounted to $17.4 million in FY2024, which was up 235.72% from $5.2 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Shares Outstanding (Diluted Average) registered a high of $145.9 million during FY2022, and its lowest value of $5.2 million during FY2023.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $17.4 million (2024), whereas its average is $56.1 million.
  • In the last 5 years, Cartesian Therapeutics' Shares Outstanding (Diluted Average) plummeted by 96.46% in 2023 and then skyrocketed by 235.72% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $101.2 million in 2020, then rose by 12.97% to $114.3 million in 2021, then increased by 27.59% to $145.9 million in 2022, then slumped by 96.46% to $5.2 million in 2023, then spiked by 235.72% to $17.4 million in 2024.